Trimipramine: Difference between revisions

Trimipramine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Newer edit →

Revision as of 20:59, 9 February 2025

A tricyclic antidepressant

Trimipramine is a tricyclic antidepressant (TCA) used in the treatment of depression. It is known for its sedative properties and is often prescribed for patients with insomnia associated with depression. Trimipramine is marketed under various brand names, including Surmontil.

Pharmacology

Trimipramine works by inhibiting the reuptake of neurotransmitters such as serotonin and norepinephrine, thereby increasing their levels in the synaptic cleft and enhancing neurotransmission. Unlike other TCAs, trimipramine has a unique mechanism of action as it also acts as an antagonist at certain serotonin receptors, which may contribute to its antidepressant effects.

Medical uses

Trimipramine is primarily used to treat major depressive disorder. It is particularly effective in patients who experience anxiety and sleep disturbances as part of their depressive symptoms. Due to its sedative effects, it is often prescribed for patients with insomnia.

Side effects

Common side effects of trimipramine include dry mouth, constipation, blurred vision, and drowsiness. It may also cause orthostatic hypotension, which is a drop in blood pressure upon standing. As with other TCAs, there is a risk of cardiotoxicity in overdose.

Interactions

Trimipramine can interact with other medications, including monoamine oxidase inhibitors (MAOIs), which can lead to serious side effects. It may also interact with alcohol, enhancing its sedative effects.

History

Trimipramine was first introduced in the 1960s and has been used in clinical practice for several decades. It remains a valuable option for patients who do not respond to other antidepressants.

Related pages

References

@@ Line 1: / Line 1: @@
-{{intro}}
+{{Short description|A tricyclic antidepressant}}
-Trimipramine is a tricyclic antidepressant used in the therapy of major (endogenous) as well as reactive (exogenous) [[depression]].
+{{Drugbox
+| verifiedrevid = 477318123
+| image = Trimipramine2DACS.svg
+| image2 = Trimipramine-ball-and-stick-model.png
+| width = 200
+}}
-{{livtox}}
+'''Trimipramine''' is a [[tricyclic antidepressant]] (TCA) used in the treatment of [[depression]]. It is known for its sedative properties and is often prescribed for patients with [[insomnia]] associated with depression. Trimipramine is marketed under various brand names, including Surmontil.
-In clinical trials, trimipramine therapy was not associated with an increased rate of elevations in serum aminotransferase levels, and it has yet to be linked to instances of clinically apparent acute liver injury.
-{{moa}}
+==Pharmacology==
-Trimipramine (trye mip' ra meen) is a tricyclic antidepressant that is believed to act by enhancing serotonergic and dopaminergic neurotransmission. Like most tricyclic antidepressants, trimipramine is a weak inhibitor of serotonin, norepinephrine and dopamine reuptake, but also has direct antagonist activity for some serotonin and adrenergic receptors. Trimipramine has been shown to alleviate symptoms of [[depression]], both in patients with neurotic or situation [[depression]] as well as those with major, endogenous [[depression]]. Trimipramine
+Trimipramine works by inhibiting the reuptake of [[neurotransmitters]] such as [[serotonin]] and [[norepinephrine]], thereby increasing their levels in the [[synaptic cleft]] and enhancing neurotransmission. Unlike other TCAs, trimipramine has a unique mechanism of action as it also acts as an antagonist at certain [[serotonin receptors]], which may contribute to its antidepressant effects.
-{{fda}}
+==Medical uses==
-{{PAGENAME}} was approved for use in the United States in 1979 and is still clinically available, although now not widely used. Trimipramine is available as capsules of 25, 50 and 100 mg generically and under the brand name Surmontil.
+Trimipramine is primarily used to treat major depressive disorder. It is particularly effective in patients who experience anxiety and sleep disturbances as part of their depressive symptoms. Due to its sedative effects, it is often prescribed for patients with insomnia.
-{{dose}}
+==Side effects==
-The typical initial dosage in adults is 75 mg daily in divided doses, which can be modified to once daily and increased in total dose based upon efficacy and tolerance to as highly as 150 to 200 mg once daily.
+Common side effects of trimipramine include [[dry mouth]], [[constipation]], [[blurred vision]], and [[drowsiness]]. It may also cause [[orthostatic hypotension]], which is a drop in blood pressure upon standing. As with other TCAs, there is a risk of [[cardiotoxicity]] in overdose.
-{{se}}
+==Interactions==
-Common side effects are diarrhea, [[nausea]], [[vomiting]], fatigue, [[drowsiness]], [[headache]], [[insomnia]], [[weight gain]] and [[sexual dysfunction]]. Rare potential side effects include increased suicide risk, cardiac arrhythmias, urinary retention and acute [[serotonin syndrome]].
+Trimipramine can interact with other medications, including [[monoamine oxidase inhibitors]] (MAOIs), which can lead to serious side effects. It may also interact with [[alcohol]], enhancing its sedative effects.
-{{antidepressants}}
+==History==
+Trimipramine was first introduced in the 1960s and has been used in clinical practice for several decades. It remains a valuable option for patients who do not respond to other antidepressants.
-{{coststubd}}
+==Related pages==
+* [[Tricyclic antidepressant]]
+* [[Major depressive disorder]]
+* [[Serotonin]]
+* [[Norepinephrine]]
+==References==
+{{Reflist}}
+[[Category:Tricyclic antidepressants]]
+[[Category:Antidepressants]]
+[[Category:Sedatives]]